Testing a web application to help patients with acute leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the effectiveness of the TRIAL web-based application designed to support individuals diagnosed with acute leukemia. The application seeks to reduce barriers to clinical trial enrollment, particularly for underrepresented groups, by providing essential information and resources. Participants will undergo screening for eligibility and complete questionnaires over a participation period of approximately 14 weeks. The study is expected to enroll around 75 participants and is funded by the National Cancer Institute and the American Society of Clinical Oncology.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 or older
* English speaking
* Ability to understand and willingness to sign written informed consent
* Clinical suspicion of acute leukemia
* Admitted to DFCI-affiliated inpatient unit

Exclusion Criteria:

* Cognitive impairment rendering the individual unable to participate in beta testing

  * This will be assessed by focused chart review and consultation with the patients' inpatient care team.
* The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
* Inability to participate in in-person application testing.
* Patients who participated in alpha-testing through protocol 23-404 (Appendix A)

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Andrew Hantel, MD — Dana-Farber Cancer Institute
• Study coordinator: Andrew Hantel, MD
• Email: Andrew_hantel@dfci.harvard.edu
• Phone: 617-582-9394

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• Examining the safety of ziftomenib combinations for patients with relapsed acute myeloid leukemia

  This study is testing if combining ziftomenib with standard treatments can safely help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 43 sites Phase 1 Kura Oncology, Inc. · Gilbert, Arizona and 44 other locations · NCT06001788

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.